Manali Kamdar on Expanding access to CAR T-cell therapy outside academic centers
Manali Kamdar, MD, will present at 4:30–5 pm on January 20, 2026, on “Expanding access to CAR T-cell therapy outside academic centers.”
Community Oncology
SOHO 2025
Leukemia News
News
Video Interviews
Drs. Jabbour, Logan, and Aldoss discuss treatment advancements in ALL
In this panel discussion at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Elias Jabbour, MD, leukemia professor at
Multiple Myeloma
News
FDA adds enterocolitis risk warning to approved CAR-T cell therapy
The US Food and Drug Administration (FDA) approved updates to the prescribing information for ciltacabtagene autoleucel (CARVYKTI). The agency added a boxed warning
Cellular Therapy
Lymphoma
Mantle Cell Lymphoma
Liso-cel receives expanded approval in R/R MCL by European Commission
The European Commission expanded approval of the CD19-directed chimeric antigen receptor T-cell therapy lisocabtagene maraleucel (liso-cel; Breyanzi®) in patients with relapsed or refractory
Multiple Myeloma
Video Interviews
Dr. Abdallah on blenrep combo approval in relapsed myeloma
In this video interview with SOHO Insider Al-Ola A. Abdallah, MD, associate professor and director of the Plasma Cell Disorder program at the
Lymphoma
Indolent B-Cell Lymphomas
News
FDA approves epcoritamab combo in R/R follicular lymphoma
The US Food and Drug Administration (FDA) approved epcoritamab (EPKINLY) in combination with rituximab, lenalidomide, and lenalidomide (RLL) for adult patients with relapsed
Ambassador Program
News
Society Updates
SOHO Egypt 2025 debuts with 2-day meeting in Cairo
The inaugural SOHO-EGYPT Meeting (November 5 to 6) was a joint session within NCI's BGO 2025 Congress ("Bridging Gaps in Oncology," November 5
Ambassador Program
News
Society Updates
SOHO KSA holds 3rd successful regional meeting
SOHO KSA held its first regional meeting in Riyadh, the Kingdom of Saudi Arabia (KSA). The two-day event was held at the Intercontinental
Multiple Myeloma
DARZALEX FASPRO® gets FDA approval to treat HR-smoldering multiple myeloma
The US Food and Drug Administration has approved daratumumab co-formulated with hyaluronidase (DARZALEX FASPRO®), as a single-agent therapy for adults with high-risk smoldering multiple
Multiple Myeloma
News
US FDA grants interchangeable designation for denosumab-bnht
The US Food and Drug Administration (FDA) granted interchangeable biosimilar designation to denosumab-bnht (Bomyntra) for patients with multiple myeloma (MM) to prevent skeletal-related